Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis

OBJECTIVE: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical out...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Tanaka, Yoshiya, McInnes, Iain B., Taylor, Peter C., Byers, Nicole L., Chen, Lei, de Bono, Stephanie, Issa, Maher, Macias, William L., Rogai, Veronica, Rooney, Terence P., Schlichting, Douglas E., Zuckerman, Steven H., Emery, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587754/
https://ncbi.nlm.nih.gov/pubmed/30058112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40680
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados